NYX

Nyctalopin (NYX) is a GPI-anchored small leucine-rich proteoglycan (SLRP) that is required for signal transmission through the depolarizing (ON) bipolar cell pathway of the inner retina, and its loss causes X-linked complete congenital stationary night blindness (CSNB1) (PMID:11062471). The protein is directed into the secretory pathway by an N-terminal ER signal sequence and retained at the extracellular face of the plasma membrane by a C-terminal GPI anchor; deletion of the GPI anchor traps the protein in the ER/Golgi and removes it from the cell surface, whereas pathogenic LRR-region mutations leave localization intact (PMID:14507859). Consistent with this circuit role, nyctalopin is expressed in the inner nuclear and ganglion cell layers throughout retinal development rather than in photoreceptors, and zebrafish nyx regulatory sequences mark a subset of ON-bipolar cells (PMID:12714669, PMID:17020638). Functionally, nyctalopin acts at the level of the depolarizing ON-bipolar cells: pharmacological ON-pathway blockade in primates recapitulates the ERG defect seen in NYX-mutant patients, and loss of nyctalopin abolishes transmission through the ON rod bipolar (AII amacrine) pathway while leaving residual signaling via rod-cone gap junctions feeding the OFF cone pathway (PMID:15331616, PMID:11581222).

1. 2000 High

   Established the gene underlying X-linked complete CSNB and identified its product as a novel GPI-anchored SLRP family member, linking a defined molecule to the long-recognized ON-pathway signaling defect.

   Evidence Positional cloning and mutation screening of 22 CSNB1 families identifying 14 distinct mutations

   PMID:11062471

   Open questions at the time

   • Did not define the subcellular localization or trafficking of the protein
   • No direct identification of binding partners or the molecular signaling step affected
2. 2001 Medium

   Resolved the precise circuit site of nyctalopin action by dissecting which rod pathway is lost, showing the defect is in ON rod bipolar transmission and not in residual rod-cone gap junction routes.

   Evidence 15-Hz scotopic flicker ERG amplitude/phase analysis in 11 NYX-confirmed patients vs 22 controls

   PMID:11581222

   Open questions at the time

   • ERG phenotyping does not reveal the molecular partners or mechanism at the bipolar cell synapse
   • Single-lab functional dissection
3. 2003 High

   Determined that nyctalopin is a cell-surface protein whose trafficking depends on its N-terminal ER signal sequence and whose plasma membrane retention requires the C-terminal GPI anchor, distinguishing trafficking-disrupting from non-trafficking pathogenic mutations.

   Evidence V5-tagged domain-deletion and mutant constructs expressed in COS-7 and HeLa cells with live-cell vs detergent-extracted immunostaining

   PMID:14507859

   Open questions at the time

   • Heterologous cell lines may not reproduce the retinal trafficking context
   • Does not identify what nyctalopin binds at the cell surface
4. 2003 Medium

   Localized nyctalopin expression to the inner nuclear and ganglion cell layers across retinal development, placing its function in inner retinal circuitry rather than photoreceptors.

   Evidence RNA in situ hybridization, immunohistochemistry, and RT-PCR in mouse and rat retina

   PMID:12714669

   Open questions at the time

   • Layer-level resolution does not assign nyctalopin to specific bipolar cell types or synaptic compartments
   • Single-lab study
5. 2004 High

   Confirmed by pharmacological epistasis that nyctalopin acts principally within the ON-pathway at depolarizing bipolar cells, with no OFF-pathway involvement.

   Evidence ERG in genotyped CSNB1-NYX patients combined with intravitreal APB (ON blocker) and PDA (OFF blocker) in primates across multiple stimulation paradigms

   PMID:15331616

   Open questions at the time

   • Pharmacology localizes the defect to the ON-pathway but does not define nyctalopin's molecular role in mGluR6 signaling complex assembly
6. 2006 Medium

   Used nyx regulatory sequences to mark ON-bipolar cells and revealed how their axon terminals develop, showing filopodial exploration before bouton consolidation as a trial-and-error synaptic targeting mechanism.

   Evidence Transgenic zebrafish expressing membrane-YFP under nyx regulatory sequences with in vivo time-lapse confocal and two-photon imaging

   PMID:17020638

   Open questions at the time

   • Reports nyx promoter activity and bipolar cell development, not a direct functional role of the nyctalopin protein in this process
   • Does not establish whether nyctalopin loss alters axonal targeting
7. 2039 Medium

   Extended the disease mechanism to noncoding NYX variants, showing a 5'UTR/exon 1 variant causes aberrant splicing and reduced nyctalopin, producing a milder phenotype.

   Evidence Whole genome sequencing, in silico splicing prediction, and minigene splicing assay (single case)

   PMID:41729106

   Open questions at the time

   • Single case and single lab
   • Minigene assay does not confirm the splicing outcome or protein reduction in patient retinal tissue

• The molecular partners through which nyctalopin enables ON-bipolar signal transmission and the biochemical step it performs at the cell surface remain undefined.
• No identified binding partner or substrate
• No structural model of the LRR or GPI-anchored protein
• Mechanism connecting surface nyctalopin to the depolarizing bipolar signaling cascade is uncharacterized